scholar.google.com › citations
May 17, 2021 · This paradigm has continued with the development and approval of multiple drugs that target ROS1 (entrectinib and crizotinib), RET ( ...
People also ask
What is fragment based drug discovery for protein kinases?
What was the first kinase drug?
What C-met inhibitors are FDA approved?
What drugs are kinase inhibitors?
Jan 1, 2018 · The review is an effort to summarize recent advancements in medicinal chemistry development of small molecule c-Met kinase inhibitors as ...
Nov 1, 2022 · Abstract. The c-MET receptor tyrosine kinase has received considerable attention as a cancer drug target yet there remains a need for inhibitors ...
Jun 21, 2023 · C-Met is a receptor tyrosine kinase belonging to the MET ... ; Cons, B. D. Fragment-based drug discovery and its application to challenging drug ...
The c-MET receptor tyrosine kinase has received considerable attention as a cancer drug target yet there remains a need for inhibitors which are selective ...
The role of MET in chemotherapy resistance | Oncogene - Nature
www.nature.com › ... › review articles
Feb 1, 2021 · Table 1 gives an overview of MET/HGF-directed drugs that have been investigated in preclinical and/or clinical research and highlights those ...
Feb 23, 2023 · We apply the binary network to epidermal growth factor receptor tyrosine kinase inhibitor selectivity by targeting the gate area and the AKT1 ...
Altogether, these results validate our ensemble docking strategy as a cost-effective functional method for drug development. Keywords: virtual screening; ...
An inhibitor of the proto-oncogene and receptor tyrosine kinase (RTK) hepatocyte growth factor receptor (c-Met; HGFR; MET) with potential antineoplastic ...
Many c-Met inhibitors have been developed in recent years. They can be categorized into different types based on their structures. Computer-aided drug design ...